EKF Diagnostics Holdings PLC Director/PDMR Shareholding (6822R)
08 Noviembre 2021 - 7:01AM
UK Regulatory
TIDMEKF
RNS Number : 6822R
EKF Diagnostics Holdings PLC
08 November 2021
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Director/PDMR Shareholding
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed
point-of-care business , announces that it has been notified that
on 8 November 2021 Julian Baines, Non-Executive Deputy Chairman,
sold a total of 250,000 ordinary shares of 1 pence each in the
Company ("Ordinary Shares") at a price of 80.76 pence per Ordinary
Share.
Following this transaction, Julian Baines' total direct and
indirect interest in the Group is 1,605,288 Ordinary Shares
representing approximately 0.35% of the Group's total issued share
capital.
The Notification of Dealing Form required in accordance with UK
MAR is set out below.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman Tel: +44 (0)29 2071 0570
Mike Salter, CEO
Richard Evans, FD & COO
Singer Capital Markets (Nominated Adviser & Tel: +44 ( 0)20 7496 3000
Joint Broker)
Aubrey Powell / George Tzimas / Tom
Salvesen
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584 391
303
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Julian Baines
--------------------------------------- -------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------
a) Position/status Non-Executive Deputy Chairman
--------------------------------------- -------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name EKF Diagnostics Holdings plc
--------------------------------------- -------------------------------------
b) LEI 213800DXTF3EAUK1AR05
--------------------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------
a) Description of the Ordinary Shares of GBP0.01 each
financial instrument,
type of instrument
Identification code GB0031509804
b) Nature of the transaction Sale of Ordinary Shares
--------------------------------------- -------------------------------------
c) Price(s) and volume(s)
---------------- ----------------
Price(s) Volume(s)
---------------- ----------------
80.76p 250,000
---------------- ----------------
d) Aggregated information
- Aggregated volume N/A - Single Transaction
- Price
e) Date of the transaction 8 November 2021
--------------------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange - AIMX
--------------------------------------- -------------------------------------
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analysers in regular use
across more than 100 countries. EKF specialises in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analysers.
EKF specialises in the development, production and worldwide
distribution of point-of-care analyzers and clinical chemistry
reagents for use in hospital and research laboratories, doctor's
offices, blood banks and for in-field anaemia screening programmes.
EKF is also a bulk manufacturer of enzymes and has custom
manufacturing facilities in the across sites in the US, UK and
Europe for a variety of life science products. Demand for contract
manufacturing of COVID-19 sample collection tests and kits has
grown dramatically during the pandemic, however the capabilities
can be applied to other areas of diagnostic testing, molecular
disease and forensic test manufacture.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBDBDBSUGDGBI
(END) Dow Jones Newswires
November 08, 2021 08:01 ET (13:01 GMT)
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
